May 12, 2021 ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board
Mar 22, 2021 ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
Feb 2, 2021 ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
Nov 9, 2020 ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease